On CNBC's "Fast Money," Bonawyn Eison advised a viewer who owns the October $40 calls in Pfizer Inc. PFE to roll the position if the stock doesn‘t move in a short time. He likes Pfizer's valuation and the fact that the company is spinning off its generic business and he sees a lot of tailwinds for the stock.
Carter Worth thinks Pfizer goes into the bucket of the large-cap laggers that have the potential to catch up. He would take some profits in Apple AAPL and put that money to work in Pfizer. Worth added that it's enough time until October, if things go well, and he would hold the call option.
Karen Finerman likes the stock. She thinks that there is so much pressure to charge very little for the Covid-19 vaccine. She would rather own SPDR S&P Biotech XBI or iShares NASDAQ Biotechnology Index IBB.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.